(MedPage Today) — GLP-1 agonists may have little impact on risk of obesity-related cancers, according to a systematic review and meta-analysis of randomized studies. (Annals of Internal Medicine)
The FDA granted accelerated approval for the subcutaneous…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/119188
Author :
Publish date : 2025-12-26 17:00:00
Copyright for syndicated content belongs to the linked Source.
